Medium-dose triptolide not only significantly reduced arthritis scores and levels of IL-6 and IL-17A, but also caused substantially less ovarian damage (E2, estrous cycles) compared to the high-dose group. This evidence concerns the gene IL17A and arthritic joint disease.